Aclaris upgraded to overweight by Cantor on in-licensing deal

Cantor has upgraded Aclaris Therapeutics ( NASDAQ: ACRS ) to overweight from neutral, citing the company's recent in-licensing of two drug candidates from China’s Biosion and concurrent equity raise. Calling the drug candidates potential blockbusters, Cantor said its DCF analysis shows around 280% upside to.